Global DNA Damage Response Drugs Market: Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

August 2020 | 247 pages | ID: G7A9338B0108EN
BIS Research Inc.

Abstracts

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.

Market Report Coverage - DNA Damage Response Drugs

Market Segmentation

• Commercialized Drugs – Lynparza, Talzenna, Zejula, and Rubraca
• Pipeline Analysis (by Mechanism of Action)- PARP Inhibitor, WEE1 Kinase Inhibitor, ATR Kinase Inhibitor, Aurora B Inhibitor, and DNA-PK Inhibitor, and Others
• Application – Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and Prostate Cancer

Regional Segmentation

• North America – U.S., Canada
• Europe – Germany, France, U.K., Italy, Spain, Switzerland, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Australia, and Rest-of-Asia-Pacific (RoAPAC)
• Latin America – Brazil, and Rest-of-the-Latin America
• Rest-of-the-World

Growth Drivers

• Rising Global Prevalence of Cancer
• Favourable Regulatory Environment
• Increasing Oncology R&D Expenditure
• Increase in Adoption of Precision Medicine in Cancer Treatment

Market Challenges

• High Cost Hindering the Adoption Rate
• Unfavorable Reimbursement Scenario
• Safety Concerns Pertaining to Severe Adverse Effects

Market Opportunities

• Massive Scope in Emerging Regions

Key Companies Profiled

AbbVie Inc., AstraZeneca plc, Bayer AG, BeiGene Ltd., Clovis Oncology, Debiopharm International SA, Eli Lilly & Company, GlaxoSmithKline plc, Merck KGaA, NMS Group S.p.A, Onxeo SA, Pfizer Inc., Repare Therapeutics, Sierra Oncology, Inc., and Zentalis Pharmaceuticals, LLC

Key Questions Answered in this Report:

• What are the major market drivers, challenges, and opportunities in the global DNA damage response drugs market?
• What are the underlying structures resulting in the emerging trends within the global DNA damage response drugs market?
• What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for the DNA damage response drugs?
• What is the pricing and reimbursement scenario for DNA damage response drugs market?
• What is the implication of the COVID-19 pandemic on the oncology research?
• What are the potential DNA damage response drugs present in the pipeline?
• What is the clinical landscape of DNA damage response drugs market?
• How is each segment of the market expected to grow during the forecast period from 2020 to 2030? What is the anticipated revenue to be generated by each of the segments on the basis of:
• Commercialized Drugs (Lynparza, Talzenna, Zujula, and Rubraca)
• Potential Pipeline Drugs (PARP Inhibitor, WEE1 Kinase Inhibitor, ATR Kinase Inhibitor, Aurora B Inhibitor, DNA-PK Inhibitor, and Others)
• Application (Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and Prostate Cancer)
• Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• Who are the leading players with significant offerings to the global DNA damage response drugs market? What is the expected market dominance for each of these leading players?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the current treatment gaps, and how are DNA damage response drugs anticipated to fill these gaps?
• How does cancer burden impact the development of DNA damage response drugs worldwide?
• What are the unmet needs that are currently being faced?

Market Overview

Our healthcare experts have found DNA damage response drugs industry to be one of the most rapidly evolving markets. The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.

The market is favored by the developments in the field of oncology research for discovering underlying molecular mechanisms of cancerous cells for the development of novel therapeutics. Moreover, the growing cases of advanced cancer worldwide has significantly escalated the need for developing DNA damage response drugs for solving cancer unmet needs. These drugs have unprecedented potential in terms of offering a selective and efficient tolerated treatment approach for improving cancer survival rates.

Within the research report, the market is segmented on the basis of commercialized drugs, pipeline analysis (by mechanism of action), application, and region. The commercialized drugs segment contains the revenue which is expected to be generated by the successful launch of commercialized drugs that are in Phase III clinical trials and are being evaluated for other cancer indications based on different biomarkers. The pipeline analysis (by mechanism of action) segment covers non-commercialized DNA damage response drugs that are currently in Phase III clinical trials and are being developed as a monotherapy treatment for various cancer indications. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among the pharmaceutical companies to invest in the development of small molecule cancer drugs. Due to the diverse product and pipeline portfolio and intense market penetration, AstraZeneca plc has been a pioneer in this field and has been a significant competitor in this market.

Several other companies such as GlaxoSmithKline plc, Pfizer Inc., and Clovis Oncology, have also launched their respective DNA damage response drugs, such as Zejula, Talzenna, and Rubraca, respectively, to compete with Lynparza’s market dominance.

On the basis of region, North America holds the largest share of DNA damage response drugs market due to the availability of capital and cancer research expertise, growing need to develop novel cancer therapeutics, and high adoption of precision medicine, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Contents

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 RESEARCH SCOPE

2.1 Scope of the Study
2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 DNA Damage Response Drugs in Oncology: Research Methodology
3.2 Data Sources
  3.2.1 Primary Data Sources
  3.2.2 Secondary Data Sources
3.3 Market Estimation Model

4 MARKET OVERVIEW

4.1 Introduction
4.2 Importance of DDR Pathways in Oncology
4.3 Key Strategies for Targeting DDR Pathways
4.4 DDR Drugs Commercialization Landscape
4.5 COVID-19 Impact on Oncology Clinical Research
4.6 Market Size and Growth Potential, $Million, 2019-2030
  4.6.1 North America
  4.6.2 Europe
  4.6.3 Asia-Pacific (APAC)
  4.6.4 Latin America (LATAM)
  4.6.5 Rest-of-the-World (RoW)

5 INDUSTRY INSIGHTS

5.1 Overview
5.2 Legal Requirements and Frameworks in the U.S.
  5.2.1 Clinical Trial Authorization
  5.2.2 Marketing Authorization
  5.2.3 Post-Authorization Regulations
5.3 Legal Requirements and Frameworks in Europe
  5.3.1 Centralized Procedure
  5.3.2 Decentralized Procedure
  5.3.3 Mutual-Recognition Procedure
  5.3.4 National Procedure
5.4 Legal Requirements and Frameworks in Asia-Pacific
  5.4.1 China
  5.4.2 Japan
5.5 Patent Analysis

6 MARKET DYNAMICS

6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
  6.3.1 Rising Global Prevalence of Cancer
  6.3.2 Favorable Regulatory Environment
  6.3.3 Increasing Oncology R&D Expenditure
  6.3.4 Increase in Adoption of Precision Medicine in Cancer Treatment
6.4 Market Restraints
  6.4.1 High Cost Hindering the Adoption Rate
  6.4.2 Unfavorable Reimbursement Scenario
  6.4.3 Safety Concerns Pertaining to Severe Adverse Effects
6.5 Market Opportunity
  6.5.1 Massive scope in Emerging Regions

7 COMPETITIVE LANDSCAPE

7.1 Key Strategies and Developments
  7.1.1 Product Approvals and Other Activities
  7.1.2 Synergistic Activities
  7.1.3 Product Launch and Updradations
  7.1.4 Business Expansion and Funding
  7.1.5 Mergers and Acquisitions
7.2 Market Share Analysis, 2018-2019
7.3 Growth Share Analysis (by Commercialized Drugs)

8 EPIDEMIOLOGY ANALYSIS FOR DNA DAMAGE RESPONSE DRUGS

9 CLINICAL LANDSCAPE

9.1 By Phase of Development
9.2 By DDR Pathway Target
9.3 By Oncology Specialty

10 GLOBAL DNA DAMAGE RESPONSE DRUGS MARKET, BY COMMERCIALIZED DRUGS ($MILLION), 2019-2030

10.1 Overview
10.2 Lynparza
10.3 Talzenna
10.4 Zejula
10.5 Rubraca

11 DNA DAMAGE RESPONSE DRUGS, BY POTENTIAL PIPELINE DRUGS

11.1 Overview
11.2 PARP Inhibitor
  11.2.1 Phase III
    11.2.1.1 Pamiparib
    11.2.1.2 Veliparib
    11.2.1.3 Fluzoparib
  11.2.2 Phase II
  11.2.3 Phase I
11.3 WEE1 Kinase Inhibitor
  11.3.1 Phase I
11.4 ATR Kinase Inhibitor
  11.4.1 Phase II
  11.4.2 Phase I
11.5 Aurora B Kinase Inhibitor
  11.5.1 Phase II
11.6 DNA-PK Inhibitors
  11.6.1 Phase II
  11.6.2 Phase I
11.7 Others
  11.7.1 Phase II
  11.7.2 Phase I

12 GLOBAL DNA DAMAGE RESPONSE DRUGS MARKET, BY APPLICATION, ($MILLION), 2019-2030

12.1 Overview
12.2 Ovarian Cancer
12.3 Breast Cancer
12.4 Pancreatic Cancer
12.5 Prostate Cancer

13 GLOBAL DNA DAMAGE RESPONSE DRUGS MARKET, BY REGION ($MILLION), 2019-2030

13.1 Overview
13.2 North America
  13.2.1 U.S.
  13.2.2 Canada
13.3 Europe
  13.3.1 Germany
  13.3.2 France
  13.3.3 U.K.
  13.3.4 Italy
  13.3.5 Spain
  13.3.6 Switzerland
  13.3.7 Rest-of-Europe
13.4 Asia-Pacific
  13.4.1 China
  13.4.2 Japan
  13.4.3 India
  13.4.4 Australia
  13.4.5 Rest-of-APAC
13.5 Latin America
  13.5.1 Brazil
  13.5.2 Rest-of-Latin America
13.6 Rest-of-the-World

14 COMPANY PROFILES

14.1 Overview
14.2 AbbVie Inc.
  14.2.1 Company Overview
  14.2.2 Role of AbbVie Inc. in Global DNA Damage Response Drugs Market
  14.2.3 Financials
  14.2.4 Key Insights about Financial Health of the Company
  14.2.5 SWOT Analysis
14.3 AstraZeneca plc
  14.3.1 Company Overview
  14.3.2 Role of AstraZeneca plc in Global DNA Damage Response Drugs Market
  14.3.3 Financials
  14.3.4 Key Insights about Financial Health of the Company
  14.3.5 SWOT Analysis
14.4 Bayer AG
  14.4.1 Company Overview
  14.4.2 Role of Bayer AG in Global DNA Damage Response Drugs Market
  14.4.3 Financials
  14.4.4 Key Insight about Financial Health of the Company
  14.4.5 SWOT Analysis
14.5 BeiGene, Ltd.
  14.5.1 Company Overview
  14.5.2 Role of BeiGene, Ltd. in Global DNA Damage Response Drugs Market
  14.5.3 Financials
  14.5.4 Key Insights about Financial Health of the Company
  14.5.5 SWOT Analysis
14.6 Clovis Oncology
  14.6.1 Company Overview
  14.6.2 Role of Clovis Oncology in Global DNA Damage Response Drugs Market
  14.6.3 Financials
  14.6.4 Key Insights about Financial Health of the Company
  14.6.5 SWOT Analysis
14.7 Debiopharm International SA
  14.7.1 Company Overview
  14.7.2 Role of Debiopharm International SA in Global DNA Damage Response Drugs Market
  14.7.3 SWOT Analysis
14.8 Eli Lilly & Company
  14.8.1 Company Overview
  14.8.2 Role of Eli Lilly & Company in Global DNA Damage Response Drugs Market
  14.8.3 Financials
  14.8.4 Key Insights about Financial Health of the Company
  14.8.5 SWOT Analysis
14.9 GlaxoSmithKline plc
  14.9.1 Company Overview
  14.9.2 Role of GlaxoSmithKline plc in Global DNA Damage Response Drugs Market
  14.9.3 Financials
  14.9.4 Key Insights about Financial Health of the Company
  14.9.5 SWOT Analysis
14.1 Merck KGaA
  14.10.1 Company Overview
  14.10.2 Role of Merck KGaA in Global DNA Damage Response Drugs Market
  14.10.3 Financials
  14.10.4 Key Insights about Financial Health of the Company
  14.10.5 SWOT Analysis
14.11 NMS Group S.p.A
  14.11.1 Company Overview
  14.11.2 Role of NMS Group S.p.A in Global DNA Damage Response Drugs Market
  14.11.3 SWOT Analysis
14.12 Onxeo SA
  14.12.1 Company Overview
  14.12.2 Role of Onxeo SA in Global DNA Damage Response Drugs Market
  14.12.3 Financials
  14.12.4 Key Insights about Financial Health of the Company
  14.12.5 SWOT Analysis
14.13 Pfizer Inc.
  14.13.1 Company Overview
  14.13.2 Role of Pfizer Inc. in Global DNA Damage Response Drugs Market
  14.13.3 Financials
  14.13.4 Key Insights about Financial Health of the Company
  14.13.5 SWOT Analysis
14.14 Repare Therapeutics
  14.14.1 Company Overview
  14.14.2 Role of Repare Therapeutics in Global DNA Damage Response Drugs Market
  14.14.3 SWOT Analysis
14.15 Sierra Oncology, Inc.
  14.15.1 Company Overview
  14.15.2 Role of Sierra Oncology, Inc. in Global DNA Damage Response Drugs Market
  14.15.3 Financials
  14.15.4 Key Insights about Financial Health of the Company
  14.15.5 SWOT Analysis
14.16 Zentalis Pharmaceuticals, LLC
  14.16.1 Company Overview
  14.16.2 Role of Zentalis Pharmaceuticals, LLC in Global DNA Damage Response Drugs Market
  14.16.3 SWOT Analysis

List Of Figures

LIST OF FIGURES

Figure 1: Global Prevalence of Prostate and Breast Cancer, 2012-2017
Figure 2: Steps for Obtaining Marketing Authorization in the U.S.
Figure 3: Clinical Landscape of DNA Damage Response Drugs, by Phase of Development
Figure 4: Clinical Landscape of DNA Damage Response Drugs, by Pathway Target
Figure 5: Implications of COVID-19 on Cancer Clinical Trials: Short- and Long-Term Implications
Figure 6: Global Target Population of DNA Damage Response Drugs, 2020-2030
Figure 7: Impact Analysis of Market Drivers and Market Challenges on the Global DNA Damage Response Drugs Market
Figure 8: Global DNA Damage Response Drugs Market, by Commercialized Drugs, 2019 vs. 2030 ($Million)
Figure 9: Expected Revenue of DNA Damage Response Drugs, by Potential Pipeline Drugs, 2025 vs. 2030
Figure 10: Global DNA Damage Response Drugs Market, by Application, 2019 vs. 2030 ($Million)
Figure 11: Global DNA Damage Response Drugs Market Snapshot
Figure 2.1: Global DNA Damage Response Drugs Market Segmentation
Figure 3.1: Global DNA Damage Response Drugs Market: Research Methodology
Figure 3.2: Bottom-up Approach (Segment-Wise Analysis)
Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Underlying Pathway of DNA Damage and Repair
Figure 4.2: Implications of COVID-19 on Cancer Clinical Trials: Short- and Long-Term Implications
Figure 4.3: North America DNA Damage Response Drugs Market, 2019 and 2030
Figure 4.4: Europe DNA Damage Response Drugs Market, 2019-2030
Figure 4.5: Asia-Pacific DNA Damage Response Drugs Market, 2019-2030
Figure 4.6: Latin America DNA Damage Response Drugs Market, 2019-2030
Figure 5.1: Steps for Obtaining Marketing Authorization
Figure 5.2: Share of Patents (by Ownership), 2016-2019
Figure 6.1: Global Prevalence of Breast, Prostate, and Ovarian Cancer, 2013-2017
Figure 7.1: Share of Key Developments and Strategies, January 2016 – May 2020
Figure 7.2: Product Approvals and Other Activities Share (by Company), January 2016 – May 2020
Figure 7.3: Synergistic Activities Share (by Company), January 2016 – May 2020
Figure 7.4: Product Launch and Upgradations Share (by Company), January 2016 – May 2020
Figure 7.5: Business Expansion and Funding Share (by Company), January 2016 – May 2020
Figure 7.6: Mergers and Acquisitions Share (by Company), January 2016 – May 2020
Figure 7.7: Market Share Analysis for Global DNA Damage Response Drugs Market, 2018 and 2019
Figure 7.8: Growth-Share Analysis for Global DNA Damage Response Drugs Market, (by Commercialized Drugs), 2019
Figure 8.1: Global Prevalence of Ovarian Cancer (2012-2017)
Figure 8.2: Global Prevalence of Breast Cancer (2012-2017)
Figure 8.3: Global Prevalence of Prostate Cancer (2012-2017)
Figure 8.4: Global Prevalence of Pancreatic Cancer (2012-2017)
Figure 8.5: Global Target Population of Ovarian Cancer (2020-2030)
Figure 8.6: Global Target Population of Breast Cancer (2020-2030)
Figure 8.7: Global Target Population of Pancreatic Cancer (2020-2030)
Figure 8.8: Global Target Population of Prostate Cancer (2020-2030)
Figure 9.1: DNA Damage Response Drugs: Developmental Phases
Figure 9.2: DNA Damage Response Drugs, by Pathway Target
Figure 9.3: DNA Damage Response Drugs: by Oncology Specialty
Figure 10.1: Global DNA Damage Response Drugs Market, by Commercialized Drugs, 2019-2030
Figure 10.2: Global Revenue for Lynparza, 2019-2030
Figure 10.3: Treatment Flow of Lynparza for Each Indication
Figure 10.4: Global Revenue for Talzenna, 2019-2030
Figure 10.5: Treatment Flow of Talzenna for Each Indication
Figure 10.6: Global Revenue for Zejula, 2019-2030
Figure 10.7: Treatment Plan of Zejula for Each Indication
Figure 10.8: Global Revenue for Rubraca, 2019-2030
Figure 10.9: Treatment Plan of Rubraca for Each Indication
Figure 11.1: Expected Revenue for Pamiparib (by Late Phase), 2025-2030
Figure 11.2: Expected Revenue for Veliparib (by Late Phase), 2025-2030
Figure 11.3: Expected Revenue for Fluzoparib (by Late Phase), 2025-2030
Figure 12.1: Global DNA Damage Response Drugs Market (by Application)
Figure 12.2: Global DNA Damage Response Drugs Market (by Application), 2019-2030
Figure 12.3: Global DNA Damage Response Drugs Market (by Ovarian Cancer), 2019-2030
Figure 12.4: Global DNA Damage Response Drugs Market (by Breast Cancer), 2019-2030
Figure 12.5: Global DNA Damage Response Drugs Market (by Pancreatic Cancer), 2019-2030
Figure 12.6: Global DNA Damage Response Drugs Market (by Prostate Cancer), 2019-2030
Figure 13.1: Global DNA Damage Response Drugs Market Snapshot (by Region)
Figure 13.2: Global DNA Damage Response Drugs Market (by Region), 2019-2030
Figure 13.3: Global DNA Damage Response Drugs Market Share (by Region), 2019 and 2030
Figure 13.4: North America DNA Damage Response Drugs Market, 2019-2030
Figure 13.5: North America: Market Dynamics
Figure 13.6: North America DNA Damage Response Drugs Market (by Country), 2019-2030
Figure 13.7: U.S. DNA Damage Response Drugs Market, 2019-2030
Figure 13.8: Canada DNA Damage Response Drugs Market, 2019-2030
Figure 13.9: Europe DNA Damage Response Drugs Market, 2019-2030
Figure 13.10: Europe Market Dynamics
Figure 13.11: Europe DNA Damage Response Drugs Market (by Country), 2019-2030
Figure 13.12: Germany DNA Damage Response Drugs Market, 2019-2030
Figure 13.13: France DNA Damage Response Drugs Market, 2019-2030
Figure 13.14: U.K. DNA Damage Response Drugs Market, 2019-2030
Figure 13.15: Italy DNA Damage Response Drugs Market, 2019-2030
Figure 13.16: Spain DNA Damage Response Drugs Market, 2019-2030
Figure 13.17: Switzerland DNA Damage Response Drugs Market, 2019-2030
Figure 13.18: Rest-of-Europe DNA Damage Response Drugs Market, 2019-2030
Figure 13.19: Asia-Pacific DNA Damage Response Drugs Market, 2019-2030
Figure 13.20: APAC: Market Dynamics
Figure 13.21: APAC DNA Damage Response Drugs Market (by Country), 2019-2030
Figure 13.22: China DNA Damage Response Drugs Market, 2019-2030
Figure 13.23: Japan DNA Damage Response Drugs Market, 2019-2030
Figure 13.24: India DNA Damage Response Drugs Market, 2019-2030
Figure 13.25: Australia DNA Damage Response Drugs Market, 2019-2030
Figure 13.26: RoAPAC DNA Damage Response Drugs Market, 2019-2030
Figure 13.27: Latin America DNA Damage Response Drugs Market, 2019-2030
Figure 13.28: Latin America: Market Dynamics
Figure 13.29: Latin America DNA Damage Response Drugs Market (by Country), 2019-2030
Figure 13.30: Brazil DNA Damage Response Drugs Market, 2019-2030
Figure 13.31: Rest-of-Latin America DNA Damage Response Drugs Market, 2019-2030
Figure 13.32: RoW DNA Damage Response Drugs Market, 2019-2030
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: AbbVie Inc.: Pipeline Product Portfolio
Figure 14.3: AbbVie Inc.: Overall Financials, 2017-2019
Figure 14.4: AbbVie Inc.: Revenue (by Region), 2017-2019
Figure 14.5: AbbVie Inc.: R&D Expenditure, 2017-2019
Figure 14.6: AbbVie Inc.: SWOT Analysis
Figure 14.7: AstraZeneca plc: Overall Product Portfolio
Figure 14.8: AstraZeneca plc: Pipeline Product Portfolio
Figure 14.9: AstraZeneca plc: Overall Financials, 2017-2019
Figure 14.10: AstraZeneca plc: Revenue (by Segment), 2017-2019
Figure 14.11: AstraZeneca plc: Revenue (by Region), 2017-2019
Figure 14.12: AstraZeneca plc: R&D Expenditure, 2017-2019
Figure 14.13: AstraZeneca plc: SWOT Analysis
Figure 14.14: Bayer AG: Pipeline Product Portfolio
Figure 14.15: Bayer AG: Overall Financials, 2017-2019
Figure 14.16: Bayer AG: Revenue (by Segment), 2018-2019
Figure 14.17: Bayer AG: Revenue (by Region), 2017-2019
Figure 14.18: Bayer AG: R&D Expenditure, 2017-2019
Figure 14.19: Bayer AG: SWOT Analysis
Figure 14.20: BeiGene, Ltd.: Pipeline Product Portfolio
Figure 14.21: BeiGene, Ltd.: Overall Financials: 2017-2019
Figure 14.22: BeiGene, Ltd.: Revenue (by Region), 2017-2019
Figure 14.23: BeiGene, Ltd.: R&D Expenditure, 2017-2019
Figure 14.24: BeiGene, Ltd.: SWOT Analysis
Figure 14.25: Clovis Oncology: Overall Product Portfolio
Figure 14.26: Clovis Oncology: Pipeline Product Portfolio
Figure 14.27: Clovis Oncology: Overall Financials, 2017-2019
Figure 14.28: Clovis Oncology: R&D Expenditure, 2017-2019
Figure 14.29: Clovis Oncology: SWOT Analysis
Figure 14.30: Debiopharm International SA: Pipeline Product Portfolio
Figure 14.31: Debiopharm International SA: SWOT Analysis
Figure 14.32: Eli Lilly & Company: Pipeline Product Portfolio
Figure 14.33: Eli Lilly & Company: Overall Financials, 2017-2019
Figure 14.34: Eli Lilly & Company: Revenue (by Region), 2017-2019
Figure 14.35: Eli Lilly & Company: SWOT Analysis
Figure 14.36: GlaxoSmithKline plc: Overall Product Portfolio
Figure 14.37: GlaxoSmithKline plc: Pipeline Product Portfolio
Figure 14.38: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 14.39: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 14.40: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 14.41: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 14.42: GlaxoSmithKline plc: SWOT Analysis
Figure 14.43: Merck KGaA: Pipeline Product Portfolio
Figure 14.44: Merck KGaA: Overall Financials, 2017-2019
Figure 14.45: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 14.46: Merck KGaA: Revenue (by Region), 2017-2019
Figure 14.47: Merck KGaA: R&D Expenditure, 2017-2019
Figure 14.48: Merck KGaA: SWOT Analysis
Figure 14.49: NMS Group S.p.A: Pipeline Product Portfolio
Figure 14.50: NMS Group S.p.A: SWOT Analysis
Figure 14.51: Onxeo SA: Pipeline Product Portfolio
Figure 14.52: Onxeo SA: Overall Financials, 2017-2019
Figure 14.53: Onxeo SA: Revenue (by Segment), 2017-2019
Figure 14.54: Onxeo SA: Revenue (by Region), 2017
Figure 14.55: Onxeo SA: Revenue (by Region), 2018-2019
Figure 14.56: Onxeo SA: R&D Expenditure (by Region), 2018-2019
Figure 14.57: Onxeo SA: SWOT Analysis
Figure 14.58: Pfizer Inc.: Overall Product Portfolio
Figure 14.59: Pfizer Inc.: Pipeline Product Portfolio
Figure 14.60: Pfizer Inc.: Overall Financials, 2017-2019
Figure 14.61: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 14.62: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 14.63: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 14.64: Pfizer Inc.: R&D Expenditure, 2017-2019
Figure 14.65: Pfizer Inc.: SWOT Analysis
Figure 14.66: Repare Therapeutics: Pipeline Product Portfolio
Figure 14.67: Repare Therapeutics: SWOT Analysis
Figure 14.68: Sierra Oncology, Inc.: Pipeline Product Portfolio
Figure 14.69: Sierra Oncology, Inc.: Overall Financials, 2017-2019
Figure 14.70: Sierra Oncology, Inc.: R&D Expenditure, 2017-2019
Figure 14.71: Sierra Oncology, Inc.: SWOT Analysis
Figure 14.72: Zentalis Pharmaceuticals, LLC: Pipeline Product Portfolio
Figure 14.73: Zentalis Pharmaceuticals, LLC: SWOT Analysis

List Of Tables

LIST OF TABLES

Table 4.1: Approved DNA Damage Response Drugs, May 2020
Table 6.1: Impact Analysis of Market Drivers
Table 6.2: Impact Analysis of Market Restraints
Table 6.3: Comparison of R&D Expenditure of Major Companies in Global DNA Damage Response Drugs Market, $Million, 2019 and 2018
Table 8.1: Cancer Types Treated with DNA Damage Response Drugs
Table 11.1: Pipeline of PARP Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.2: Pipeline of PARP Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.3: Pipeline of WEE1 Kinase Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.4: Pipeline of ATR Kinase Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.5: Pipeline of ATR Kinase Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.6: Pipeline of Aurora B Kinase Inhibitor in the Global DNA Damage Response Drugs Market
Table 11.7: Pipeline of DNA-PK Inhibitor in the Global DNA Damage Response Drugs Market
Table 11.8: Pipeline of DNA-PK Inhibitor in the Global DNA Damage Response Drugs Market
Table 11.9: Pipeline of Other Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.10: Pipeline of Other Inhibitors in the Global DNA Damage Response Drugs Market
Table 12.1: Marketed DNA Damage Response (DDR) Drugs for Ovarian Cancer
Table 12.2: DNA Damage Response (DDR) Drugs for Ovarian Cancer: Pipeline Products
Table 12.3: Marketed DNA Damage Response (DDR) Drugs for Breast Cancer
Table 12.4: DNA Damage Response (DDR) Drugs for Breast Cancer: Pipeline Products
Table 12.5: Marketed DNA Damage Response (DDR) Drugs for Pancreatic Cancer
Table 12.6: DNA Damage Response (DDR) Drugs for Pancreatic Cancer: Pipeline Products
Table 12.7: Marketed DNA Damage Response (DDR) Drugs for Prostate Cancer
Table 12.8: DNA Damage Response (DDR) Drugs for Prostate Cancer: Pipeline Products